Devonian Health Group Inc. (GSD)
TSX-V TSX-V Primary Summary
Devonian Health Group Inc. (GSD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Devonian Health Group Inc. ever had a stock split?
Devonian Health Group Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Luc D. Gregoire CA, CPA CEO | TSX-V Exchange | CA2518341078 ISIN |
| CA Country | 6 Employees | - Last Dividend | 19 May 2017 Last Split | - IPO Date |
Overview
Devonian Health Group Inc. is a pioneering company specializing in the development of botanical drugs, which utilizes the medicinal properties of plants to create effective pharmaceutical products. Since its inception in 2015, Devonian Health Group has established itself as a forward-thinking entity within the pharmaceutical industry, committed to addressing a range of health conditions through innovative botanical solutions. Headquartered in Québec, Canada, the company continues to advance in its research endeavors, aiming to bring new botanical drugs to market that can substantially improve patient care and outcomes.
Products and Services
- Thykamine
- Pantoprazole Magnesium
- Cleo-35
- Dermo-Cosmetics
This leading product candidate from Devonian Health Group Inc. represents a significant advancement in the treatment of ulcerative colitis and atopic dermatitis. Having completed Phase IIa clinical trial, Thykamine showcases the potential of botanical drugs to provide effective solutions for chronic inflammatory conditions, paving the way for new therapeutic options for patients.
Devonian focuses on addressing gastrointestinal health through Pantoprazole Magnesium, a drug developed for the treatment of gastric issues. This product reflects the company's commitment to expanding its portfolio to include treatments that cater to a wide range of bodily systems and conditions.
Targeting hormonal acne in women, Cleo-35 is another innovative project by Devonian Health Group. By tapping into the specific needs of women suffering from this condition, Cleo-35 aims to provide a specialized, effective treatment option that leverages botanical components for skin health and hormonal balance.
In addition to its pharmaceutical developments, Devonian Health Group Inc. also ventures into the realm of dermo-cosmetics by creating value-added products. These offerings aim to blend therapeutic effectiveness with cosmetic benefits, addressing skin issues with formulations grounded in botanical efficacy.
Moreover, Devonian Health Group extends its capabilities through the acquisition of drug and health product licenses, alongside distributing pharmaceutical products. This holistic approach ensures a wide-reaching impact in the healthcare and pharmaceutical sectors, enhancing the availability and diversity of treatment options for various conditions.
Contact Information
